SPRED1 Polyclonal Antibody
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
 
| Application  
 | WB, IHC-P, IHC-F, IF, ICC, E | 
|---|---|
| Primary Accession | Q7Z699 | 
| Reactivity | Rat, Pig, Dog, Bovine | 
| Host | Rabbit | 
| Clonality | Polyclonal | 
| Calculated MW | 50 KDa | 
| Physical State | Liquid | 
| Immunogen | KLH conjugated synthetic peptide derived from human SPRED1 | 
| Epitope Specificity | 301-400/444 | 
| Isotype | IgG | 
| Purity | affinity purified by Protein A | 
| Buffer | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. | 
| SUBCELLULAR LOCATION | Cell membrane. Membrane > caveola. Nucleus. Localized in cholesterol-rich membrane raft/caveola fractions. | 
| SIMILARITY | Contains 1 KBD domain. Contains 1 SPR (sprouty) domain. Contains 1 WH1 domain. | 
| Post-translational modifications | Phosphorylated on tyrosine. | 
| DISEASE | Defects in SPRED1 are the cause of Legius syndrome (LEGIUSS) [MIM:611431]. It is a disorder characterized mainly by cafe au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1, axillary freckling, and macrocephaly. Additional clinical manifestations include Noonan-like facial dysmorphism, lipomas, learning disabilities and attention deficit-hyperactivity. | 
| Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. | 
| Background Descriptions | The protein encoded by this gene is a member of the Sprouty family of proteins and is phosphorylated by tyrosine kinase in response to several growth factors. The encoded protein can act as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. Defects in this gene are a cause of neurofibromatosis type 1-like syndrome (NFLS). [provided by RefSeq, Jul 2008] | 
| Gene ID | 161742 | 
|---|---|
| Other Names | Sprouty-related, EVH1 domain-containing protein 1, Spred-1, hSpred1, SPRED1 | 
| Target/Specificity | Weakly expressed in embryonic cell line (HEK-293). | 
| Dilution | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-500,ELISA=1:5000-10000 | 
| Storage | Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. | 
| Name | SPRED1 | 
|---|---|
| Function | Tyrosine kinase substrate that inhibits growth-factor- mediated activation of MAP kinase (By similarity). Negatively regulates hematopoiesis of bone marrow (By similarity). Inhibits fibroblast growth factor (FGF)-induced retinal lens fiber differentiation, probably by inhibiting FGF-mediated phosphorylation of ERK1/2 (By similarity). Attenuates actin stress fiber formation via inhibition of TESK1-mediated phosphorylation of cofilin (PubMed:18216281). Inhibits TGFB-induced epithelial-to-mesenchymal transition in lens epithelial cells (By similarity). | 
| Cellular Location | Cell membrane; Peripheral membrane protein. Membrane, caveola; Peripheral membrane protein. Nucleus Note=Localized in cholesterol-rich membrane raft/caveola fractions | 
| Tissue Location | Weakly expressed in embryonic cell line HEK293. | 

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.




 
 
                                 
                                 
                                

 
                                         
                                        
 
                                         
                                         
                                         Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them. The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle. The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer. 
        

